Understanding the differences among inotropes

Intensive Care Medicine

Volumn 41, Issue 5, 2015, Pages 912-915

  Arrigo, Mattia ^a,d   Mebazaa, Alexandre ^b,c,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d APHP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT;

DRUG EFFECTS; HEART FAILURE; HUMAN; MUSCLE CONTRACTION;

CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; MUSCLE CONTRACTION;

EID: 84939959830     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-3659-7     Document Type: Article

References (15)

1. Mebazaa A, Parissis J, Porcher R et al (2011) Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37:290–301. doi:10.1007/s00134-010-2073-4
2. Cecconi M, De Backer D, Antonelli M et al (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 40:1795–1815. doi:10.1007/s00134-014-3525-z
3. Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997–1003. doi:10.1016/S0735-1097(02)02968-6
4. Papp Z, Édes I, Fruhwald S et al (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159:82–87. doi:10.1016/j.ijcard.2011.07.022
5. Hasenfuss G, Teerlink JR (2011) Cardiac inotropes: current agents and future directions. Eur Heart J 32:1838–1845. doi:10.1093/eurheartj/ehr026
6. Cleland JGF, Teerlink JR, Senior R et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378:676–683. doi:10.1016/S0140-6736(11)61126-4
7. Mebazaa A, Nieminen MS, Filippatos GS et al (2009) Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 11:304–311. doi:10.1093/eurjhf/hfn045
8. Mebazaa A, Pitsis AA, Rudiger A et al (2010) Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 14:201. doi:10.1186/cc8153
9. Koster G, Wetterslev J, Gluud C et al (2014) Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. doi:10.1007/s00134-014-3604-1
10. Pirracchio R, Parenica J, Resche Rigon M et al (2013) The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One 8:e71659. doi:10.1371/journal.pone.0071659
11. Rudiger A, Singer M (2013) The heart in sepsis: from basic mechanisms to clinical management. Curr Vasc Pharmacol 11:187–195
12. Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684. doi:10.1016/S0140-6736(07)61344-0
13. Hernandez G, Bruhn A, Luengo C et al (2013) Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med 39:1435–1443. doi:10.1007/s00134-013-2982-0
14. Morelli A, De Castro S, Teboul J-L et al (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644. doi:10.1007/s00134-005-2619-z
15. Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883–1891. doi:10.1001/jama.297.17.1883